BioFluidica
BioFluidica, a San Diego-based biotech firm, develops diagnostic platforms for disease management, specializing in circulating tumor cells.
Founded
2006BioFluidica, a San Diego-based biotech firm, develops diagnostic platforms for disease management, specializing in circulating tumor cells.
BioFluidica, founded in San Diego, is a biotechnology company focused on developing advanced diagnostic platforms for disease management. Their core mission is to revolutionize medical diagnostics through innovative liquid biopsy technologies that capture and isolate circulating tumor cells (CTCs) and other biomarkers. BioFluidica's flagship products include LiquidScan, which facilitates exosome and fetal cell isolation, and next-generation liquid biopsy solutions. The company primarily serves the healthcare market, aiming to provide more accurate and less invasive diagnostic options.
Notable figures associated with BioFluidica include its leadership team and board of directors, who bring extensive expertise in biotechnology and medical diagnostics. The company has secured significant grants and investments to advance its research and development efforts. Key achievements include the successful development and commercialization of their liquid biopsy technologies, which have the potential to significantly impact early disease detection and personalized medicine. BioFluidica's innovations are poised to enhance diagnostic accuracy and patient outcomes, making a substantial impact on the healthcare industry.
Companies similar to BioFluidica include BioCeryx, Biological Dynamics, Liquid Biotech and RareCyte.
BioFluidica was founded in 2006.
BioFluidica's headquarters is located in San Diego, CA, US.
As of Mar 23, 2022, BioFluidica has disclosed funding of $19.2M (USD). Undisclosed round amounts are excluded.
BioFluidica has 19 employees as of Feb 5, 2024.
